Explore Video

The landscape of HR+ve/HER2-negative metastatic breast cancer (MBC) has evolved significantly with the introduction of newer treatment options such as CDK4/6 inhibitors, PI3K inhibitors, and selective estrogen receptor down regulators.

3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC

Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.

Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.

PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.

Gradient Based Model based on 10 routinely used parameters (Age, Gender, Hb, WBC, MCV, Platelets, Neutrophils, Monocytes, Glucose, Creatinine) is now available to facilitate non-invasive diagnosis of MDS.